|
Heberprot-P benefits more than 31,000
Cubans
Orfilio Peláez
Cuba
has reduced the risk of amputation caused by ulcers
in diabetics by more than 78% thanks to the
implementation of a comprehensive program across all
provinces, directed toward treating patients
suffering from the problem, including through the
use of Heberprot-P.
 Developed
by specialists from the
Cuban Center
for
Genetic
Engineering and Biotechnology
(CIBG),
in collaboration with other entities, Heberprot-P is
the only drug worldwide, capable of
enhancing the
healing of
such complex
lesions,
and which has benefited
more than
31,000 Cubans.
In
addition, for three consecutive years the diabetes
mortality rate in the country has continued to
decrease, while 84% of suffers reach the same life
expectancy as non-diabetic Cubans (around 78 years).
These remarkable results will be presented at the
International Congress on the Control of Diabetes,
which will be take place in Varadero from December
10-12.
According to Mailyn Palmero Molina, member of the
event organizing committee, confirmed to attend is
Mr. Michael Hirst, President of the International
Diabetes Federation (IDF), an organization which
includes some 230 national associations from 170
countries.
|
